Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular, Oncologie Form Cancer Drug Biomarker Partnership

NEW YORK (GenomeWeb) — HTG Molecular Diagnostics announced today that it has signed a master agreement to help Oncologie develop biomarkers for its immuno-oncology drug candidates.

Specific terms of the deal were not disclosed.

Oncologie currently has two drugs in its pipeline: the phase II immune-modulatory monoclonal antibody bavituximab, and the phase III immunomodulator and toll-like receptor 9 agonist lefitolimod. HTG offers next-generation sequencing-based molecular profiling instruments and assays, as well as related lab services.

"We believe HTG's technology and assay development capabilities will assist our clinical development efforts as we strive to bring innovative new medicines to cancer patients globally," Oncologie Founder and CEO Laura Benjamin said in a statement.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.